Analysts at Susquehanna initiated coverage on Adient PLCADNT with a Neutral rating. The price target for Adient is set to $56. Adient shares closed at $55.86 on Friday.
Analysts at Rodman & Renshaw initiated coverage on Imprimis Pharmaceuticals Inc IMMY with a Buy rating. The price target for Imprimis Pharmaceuticals is set to $5. Imprimis Pharmaceuticals shares closed at $2.61 on Friday.